Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis

Documenti analoghi

• Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
  di: Seoung Hoon Kim
  Pubblicazione: (2026)
• Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
  di: Wenxiao Fan, et al.
  Pubblicazione: (2025)
• Hepatic steatosis index for prediction of metabolic dysfunction‐associated steatotic liver disease ( MASLD ) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy
  di: Alpesh Goyal, et al.
  Pubblicazione: (2025)
• Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
  di: Sarra Smati, et al.
  Pubblicazione: (2024)
• Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
  di: Yuqing Ma, et al.
  Pubblicazione: (2025)